Skip to main content
ARGX
NASDAQ Life Sciences

ARGENX Presents Positive Long-Term VYVGART Data in Myositis & Sjogren's, Reinforcing Safety Profile

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$790.71
Mkt Cap
$49.94B
52W Low
$510.055
52W High
$934.62
52W Position info
55% above low
Off High info
15% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ARGX sits 55% above its 52-week low of $510.055.

Summary

ARGENX SE announced positive long-term clinical data for its drug VYVGART in myositis and Sjogren's disease, highlighting sustained patient benefits and a consistent safety profile across multiple autoimmune conditions.


Key Events · Product Development and Regulatory · ARGX

  • Sustained Benefit in Myositis

    ALKIVIA+ data showed VYVGART provided sustained, clinically meaningful improvements and consistent safety in myositis patients through 52 weeks, with 37.5% maintaining major TIS improvement.

  • Maintained Response in Sjogren's Disease

    RHO+ data indicated maintenance of response in Sjogren's disease patients following a switch to biweekly dosing, with low disease activity scores (median ClinESSDAI 2.0-2.5) at 72 weeks.

  • Reinforced Safety Profile

    A cross-indication safety analysis confirmed VYVGART's consistent and well-tolerated safety profile across 834 treated patients and over 1,300 patient-years in autoimmune rheumatic diseases.

  • Upcoming Phase 3 Readouts

    Topline results for the Phase 3 ALKIVIA study in myositis are expected in Q3 2026, and for the Phase 3 UNITY trial in Sjogren's disease in H2 2027.


Analysis · ARGX · Life Sciences

This 6-K details new clinical data for argenx's key drug, VYVGART, presented at EULAR 2026. The data from extension studies in myositis and Sjogren's disease show sustained clinical benefits and a consistent, favorable safety profile across multiple autoimmune rheumatic diseases. This reinforces the drug's broad potential and supports ongoing Phase 3 trials, which are critical for future label expansions and market growth.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARGX was trading at $790.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.9B. The 52-week trading range was $510.06 to $934.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARGX - Latest Insights

ARGX
Oct 22, 2026, 8:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $854.00
Real-time Price: $921.00 info
Change: +$67.00 (+8%) info
Market Cap: $57.544B info
ARGX
Oct 08, 2026, 6:51 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $795.20
Real-time Price: $921.00 info
Change: +$125.80 (+16%) info
Market Cap: $57.544B info
ARGX
Oct 08, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $791.00
Real-time Price: $921.00 info
Change: +$130.00 (+16%) info
Market Cap: $57.544B info
ARGX
Sep 29, 2026, 8:38 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $970.55
Real-time Price: $921.00 info
Change: -$49.55 (-5%) info
Market Cap: $57.544B info
ARGX
Aug 27, 2026, 9:27 AM EDT
Filing Type: SC TO-T/A
Importance Score:
8
Price at Filing: $1,018.58
Real-time Price: $921.00 info
Change: -$97.58 (-10%) info
Market Cap: $57.544B info